Research Bulletin
Published peptide studies
The Mitochondrial Genome-Encoded Peptide MOTS-c Interacts with Bcl-2 to Alleviate Nonalcoholic Steatohepatitis Progression
Published in Cell Reports, this study demonstrated that the mitochondrial-derived peptide MOTS-c alleviates diet-induced mitochondrial metabolic deficiency, liver steatosis, cellular apoptosis, inflammation, and fibrosis in a nonalcoholic steatohepatitis (NASH) model. The researchers found that MOTS-c interacts directly with the protein Bcl-2, suppresses its ubiquitination, and increases its stability, thereby maintaining mitochondrial homeostasis under metabolic stress. These findings identify a novel molecular mechanism through which MOTS-c may offer protection against NASH progression.
Topically Applied GHK as an Anti-Wrinkle Peptide: Advantages, Problems and Prospective
This 2024 review published in BioImpacts examined the evidence for GHK-Cu and its palmitated derivative Pal-GHK as topical anti-aging agents, concluding that cellular studies clearly support GHK-Cu's classification as an effective anti-wrinkle ingredient. The authors noted that while copper complexation and chemical modification improve the peptide's skin permeability, clinical trial data remain surprisingly sparse given its widespread cosmetic use. Emerging delivery strategies — including cell-penetrating peptide carriers, ionic liquid microemulsions, and microneedle pretreatment — were identified as promising avenues to improve skin permeation and unlock GHK-Cu's full regenerative potential.
Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 Three-Year Analysis)
This phase 3, double-blind, randomized controlled trial found that three years of tirzepatide treatment in participants with obesity and prediabetes produced substantial, sustained weight reduction and a markedly lower risk of progression to type 2 diabetes compared to placebo. The study followed 1,032 participants with both obesity and prediabetes from the larger SURMOUNT-1 cohort. Results position tirzepatide as a dual GIP/GLP-1 receptor agonist with significant long-term metabolic benefits in preclinical research populations.
Exploring the Beneficial Effects of GHK-Cu on an Experimental Model of Colitis and the Underlying Mechanisms
This in vivo and in vitro study investigated GHK-Cu's therapeutic mechanisms in ulcerative colitis (UC), a chronic inflammatory bowel disease characterized by mucosal damage and impaired barrier function. Researchers found that GHK-Cu significantly upregulated SIRT1 expression in colon tissues, identifying it as a novel potential SIRT1 activator, and demonstrated that it modulates STAT3-mediated inflammatory signaling. The findings suggest GHK-Cu may offer a targeted anti-inflammatory mechanism relevant to gut mucosal protection.
Mitochondria-Derived Peptide MOTS-c Restores Mitochondrial Respiration in the Type 2 Diabetic Heart
Using a high-fat diet and low-dose streptozotocin rat model of type 2 diabetes (T2D), this study found that MOTS-c treatment effectively delayed weight gain and was associated with restoration of mitochondrial respiratory function in cardiac tissue. The research is consistent with prior findings that circulating MOTS-c levels are lower in T2D individuals compared to healthy controls, suggesting a potential link between this mitochondrial-derived peptide and diabetic cardiomyopathy. Authors propose exogenous MOTS-c as a promising strategy for enhancing muscle and cardiac mitochondrial function in metabolic disorders.
The Stable Gastric Pentadecapeptide BPC 157: Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity
This 2024 review highlights BPC-157's broad cytoprotective and pleiotropic properties, noting its stability in human gastric juice and its capacity to counteract disturbances across multiple neurotransmitter systems including dopamine, serotonin, glutamate, GABA, and the NO system. The authors present a network of evidence suggesting BPC-157 modulates relevant receptors—including VEGF and growth hormone receptors—and may act as a mediator of cytoprotection across organ systems. The study underscores BPC-157's potential relevance to both gastrointestinal and neurological research models.
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
This foundational mechanistic study demonstrated that the tripeptide KPV is actively transported into intestinal epithelial and immune cells via the PepT1 transporter, where it inhibits NF-κB and MAP kinase inflammatory signaling pathways at nanomolar concentrations. Oral administration of KPV significantly reduced colitis severity in two established mouse models (DSS- and TNBS-induced), as confirmed by histological assessment and reduced pro-inflammatory cytokine expression. The authors concluded that KPV's PepT1-mediated cellular uptake makes it a strong candidate for further investigation as an inflammatory bowel disease therapeutic.
Mitochondrial-Encoded Peptide MOTS-c Prevents Pancreatic Islet Cell Senescence to Delay Diabetes
This study examined how MOTS-c affects pancreatic islet aging using aged mouse models and nonobese diabetic mice. Treatment with MOTS-c reduced islet cell senescence by modulating nuclear gene expression and key metabolites involved in beta-cell aging, and improved glucose intolerance in treated animals. The researchers also observed that circulating MOTS-c levels are lower in human type 2 diabetes patients compared to healthy controls, supporting its relevance to metabolic disease research.
Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial
This Nature Medicine phase 2a substudy evaluated retatrutide — a novel triple agonist of GIP, GLP-1, and glucagon receptors — in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who had at least 10% liver fat at baseline. Building on the parent 48-week obesity trial, which showed weight reductions of up to 24.2%, the substudy assessed mean relative change in liver fat at 24 weeks and found significant reductions, highlighting the glucagon receptor component's role in driving hepatic fat oxidation. The results position retatrutide as a particularly compelling research candidate for MASLD alongside its established metabolic and weight-loss profile.
PepT1-Targeted Nanodrug Based on Co-Assembly of Anti-Inflammatory Peptide KPV and Immunosuppressant for Combined Treatment of Acute and Chronic DSS-Induced Colitis
This 2024 study developed a co-assembled nanodrug pairing the tripeptide KPV with an immunosuppressant, targeting the PepT1 transporter that is upregulated in inflamed colon tissue, to treat both acute and chronic colitis models. The formulation demonstrated restored tight junction proteins (ZO-1, Claudin-5, Occludin-1) and improved colonic mucosal integrity in DSS-induced colitis mice. Results suggest that leveraging KPV's PepT1-mediated cellular uptake in a targeted nanoparticle platform significantly enhances its anti-inflammatory efficacy.
Safety of Intravenous Infusion of BPC-157 in Humans: A Pilot Study
This IRB-approved pilot study assessed the safety of intravenous BPC-157 administration in two healthy adult participants, monitoring blood work and vital signs before and after each infusion. Intravenous infusion of up to 20 mg of BPC-157 showed no adverse effects and was well-tolerated in both subjects. The authors concluded that the results support the safety of intravenous BPC-157 in humans, while noting that larger future studies are needed to confirm these preliminary findings.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
This phase 3 randomized controlled trial (SUMMIT) found that tirzepatide significantly reduced the composite risk of death from cardiovascular causes or worsening heart failure compared to placebo in patients with obesity and heart failure with preserved ejection fraction. Participants also showed meaningful improvements in health status and functional outcomes. The study reinforces the broad cardiometabolic benefits of this dual GIP/GLP-1 receptor agonist beyond glycemic and weight control.
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH Trial)
This phase 2 randomized controlled trial (SYNERGY-NASH) evaluated tirzepatide over 52 weeks in participants with metabolic dysfunction-associated steatohepatitis (MASH) and moderate or severe liver fibrosis. Treatment with tirzepatide was significantly more effective than placebo at achieving resolution of MASH without worsening of fibrosis, opening a potential new therapeutic application for this dual incretin receptor agonist peptide. The authors noted that larger and longer trials are needed to further confirm efficacy and safety in this population.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
This narrative review examined BPC-157's therapeutic potential across musculoskeletal injuries, finding consistent preclinical evidence that the peptide promotes tendon, muscle, and ligament healing through angiogenic, anti-inflammatory, cytoprotective, and tissue-regenerative mechanisms. The authors noted that BPC-157 activates both VEGF-dependent and VEGF-independent pathways to support nitric oxide production, angiogenesis, and vascular stability. Only three small pilot human studies have been completed to date, with no adverse effects reported, though the authors emphasize that large-scale rigorous trials are still needed.
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
This phase 2 randomized controlled trial published in the New England Journal of Medicine evaluated tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis over 52 weeks. Researchers found that tirzepatide was significantly more effective than placebo at resolving MASH without worsening fibrosis. The findings suggest that tirzepatide's dual GIP/GLP-1 receptor agonism may offer a meaningful therapeutic approach for liver disease beyond its established metabolic effects.
Lysine-Proline-Valine Peptide Mitigates Fine Dust-Induced Keratinocyte Apoptosis and Inflammation by Regulating Oxidative Stress and Modulating the MAPK/NF-κB Pathway
This study investigated KPV, the C-terminal tripeptide of alpha-melanocyte stimulating hormone, against particulate matter (PM10)-induced oxidative damage and inflammation in human HaCaT keratinocytes. KPV treatment restored cell viability, reduced IL-1β secretion, and blocked ROS-mediated caspase-1 activation in cells stressed by PM10 exposure. In a 3D skin model, KPV effectively attenuated inflammatory cell death induced by PM10, pointing to its potential as a protective agent against environmental pollutant-related skin damage.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
This 2025 narrative review critically evaluates BPC-157 from a biopharmaceutical and drug-development perspective, examining its physicochemical and pharmacokinetic properties, formulation challenges across routes of administration, and the regulatory barriers that currently limit clinical advancement. Despite over three decades of preclinical research demonstrating cytoprotective and regenerative activity across multiple organ systems, the authors note that no approved formulation, validated dosing regimen, or completed Phase II clinical trial yet exists. The review highlights the pharmacokinetic–pharmacodynamic disconnect observed in preclinical studies as a key translational challenge.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
This 2024 Phase III randomized controlled trial published in the New England Journal of Medicine evaluated tirzepatide in patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity. At 52 weeks, tirzepatide reduced the apnea–hypopnea index (AHI) by approximately 25 events per hour compared to roughly 5 events per hour with placebo, a clinically meaningful difference. The study also found reductions in body weight, hypoxic burden, hsCRP, and systolic blood pressure, along with improved sleep-related patient-reported outcomes.
PepT1-Targeted Nanodrug Based on Co-Assembly of Anti-Inflammatory Peptide and Immunosuppressant for Combined Treatment of Acute and Chronic DSS-Induced Colitis
Published in Frontiers in Pharmacology (2024), this study co-assembled the tripeptide KPV with the immunosuppressant FK506 into targeted nanoparticles designed to be taken up by the intestinal PepT1 transporter. In both acute and chronic dextran sodium sulfate (DSS)-induced colitis mouse models, the nanodrug formulation demonstrated improved anti-inflammatory outcomes, including restoration of tight junction proteins (ZO-1, Claudin-5, Occludin-1). The findings support KPV's continued investigation as a targeted delivery candidate for inflammatory bowel disease.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
This systematic review analyzed 36 studies (35 preclinical, 1 clinical) published between 1993 and 2024, finding that BPC-157 enhances growth hormone receptor expression, promotes angiogenesis, and reduces inflammatory cytokines. In preclinical models, the peptide improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injury models. A single human pilot study reported that 7 of 12 patients with chronic knee pain experienced relief lasting over six months following a single intra-articular injection.
Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3-Year Analysis)
This phase 3, double-blind, randomized controlled trial followed 2,539 participants with obesity — including 1,032 with prediabetes — for three years, finding that tirzepatide produced substantial and sustained reductions in body weight compared to placebo. Notably, participants with prediabetes who received tirzepatide showed a markedly lower risk of progressing to type 2 diabetes. These long-term results from the SURMOUNT-1 trial reinforce the dual GLP-1/GIP receptor agonist's potential role in both weight management and metabolic disease prevention.
Mitochondria-Derived Peptide MOTS-c Restores Mitochondrial Respiration in Type 2 Diabetic Heart
Using a high-fat diet and low-dose streptozotocin rat model of type 2 diabetes, this study found that exogenous MOTS-c treatment effectively delayed weight gain and showed promise in restoring mitochondrial respiratory function in diabetic cardiac tissue, where mitochondrial dysfunction is a key driver of reduced contractile performance. The results are consistent with prior reports that blood MOTS-c levels are lower in individuals with type 2 diabetes, gestational diabetes, and coronary endothelial dysfunction, supporting the peptide's role in metabolic homeostasis. These findings position MOTS-c as a promising investigational strategy for studying mitochondrial function in metabolic heart disease.
GHK-Cu as a Multifunctional Copper Peptide: Synthesis Routes, Process Engineering and Emerging Applications
This comprehensive review examined the molecular mechanisms, production strategies, and emerging applications of GHK-Cu, finding that the peptide plays multifaceted biological roles in tissue repair, anti-inflammatory regulation, extracellular matrix remodeling, and redox homeostasis. The authors highlight GHK-Cu's evolution from a dermatological ingredient into a model system linking coordination chemistry and peptide bioactivity. The review also covers advances in scalable biomanufacturing approaches, including high-cell-density fermentation and copper complex stabilization.